Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
| ▸ | ADH1B | P00325 | 1/20 | 0.30 |
| ▸ | ADH1C | P00326 | 1/20 | 0.30 |
| ▸ | ADH1A | P07327 | 1/20 | 0.30 |
| ▸ | ADH7 | P40394 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28607303 | 0.84 | ADH1B (0.36) | GPR52FOLH1ADH1BADH1CADH1A | |
| SCHEMBL28552014 | 0.78 | TLR8 (0.37) | — | |
| SCHEMBL5174795 | 0.78 | IDO1 (0.36) | MAPTHDAC8FOLH1 | |
| SCHEMBL1738495 | 0.77 | MAPT (0.33) | MAPTHDAC8 | |
| SCHEMBL910692 | 0.76 | GABRA1 (0.39) | MAPT | |
| SCHEMBL8414772 | 0.76 | MAPT (0.32) | MAPTHDAC8 | |
| SCHEMBL143458 | 0.75 | MTNR1A (0.49) | MAPT | |
| SCHEMBL587837 | 0.75 | IDO1 (0.36) | MAPTHDAC8 | |
| SCHEMBL4444470 | 0.74 | LMNA (0.50) | — | |
| SCHEMBL1338205 | 0.74 | TAAR1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7574340-B2 | Small molecules and a pharmacophore model for inhibition of botulinum toxin and methods of making and using thereof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2009-08-11 | — | — | US | disclosed |
| US-20050153945-A1 | Small molecules and a pharmacophore model for inhibition of botulinum toxin and methods of making and using thereof | ARMY, UNITED STATES | 2005-07-14 | — | — | US | disclosed |
| WO-2005026193-A2 | SMALL MOLECULES AND A PHARMACOPHORE MODEL FOR INHIBITION OF BOTULINUM TOXIN AND METHODS OF MAKING AND USING THEREOF | UNITED STATES ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153945-A1 | Small molecules and a pharmacophore model for inhibition of botulinum toxin and methods of making and using thereof | MMP2, RAC2, RAC1 | MAPT 4644/4885HDAC8 2856/4885GPR52 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.